A Phase 3 Trial of Lenvatinib vs Sorafenib in First-line Treatment of Patients With Unresectable Hepatocellular Carcinoma (REFLECT Study)

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Disclosures

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Study Rationale

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Study Schema

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Assessments and Statistical Analysis

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Patient Characteristics

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Patient Characteristics (continued)

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Primary Endpoint: Kaplan-Meier Estimate of OS

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Forest Plot of OS in Subgroup Analyses<br />

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Secondary Endpoint: Kaplan-Meier Estimate of PFS by mRECIST

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Forest Plot of PFS in Subgroup Analyses

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Secondary Endpoint: Kaplan-Meier Estimate of TTP

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Maximum Change in Tumor Size by mRECIST

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 OS Adjusted by Baseline AFP (<200 ng/mL and 200 ng/mL)

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Study Drug Administration

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Overview of Treatment-emergent Adverse Events

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Most Frequent TEAEs ( 15%)

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Health-related Quality of Life

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Biomarker Analyses

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Conclusions

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Slide 21

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Back up

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting

 Maximum Change in Tumor Size by mRECIST

Presented By Ann-Lii Cheng at 2017 ASCO Annual Meeting